You are here

Industry Sponsorship Influences Clinical Trial Findings, Researchers Claim

Study calls for new look at how bias is handled in guidelines and reviews (Dec. 12)

Studies reporting the results of industry-sponsored clinical trials present a more favorable picture of the effects of drugs and medical devices than do those reporting on non–industry-sponsored trials, according to a new Cochrane systematic review. The researchers call for a rethink of the way that industry bias is handled in medical guidelines and reviews.

The new report was published online in The Cochrane Library.

The outcomes of clinical trials influence the recommendations that physicians make about drugs and other medical interventions. Therefore, the report says, it is important that trials are designed, carried out, and reported on without bias towards particular products. The fact that trials are increasingly sponsored by industry makes it difficult to ensure that this is always the case. The report points out that an industry sponsor can influence study results and how they are reported to present their company and products in a better light — for example, by selectively reporting positive results. Previous reviews showed that industry-sponsored drug trials produce more favorable results, but the researchers wanted to expand the evidence base to medical devices and find out if new requirements for clinical trial registration had made any difference.

The researchers reviewed 48 studies on drugs and medical devices. The drugs and devices being studied were prescribed for a wide range of diseases and conditions, from heart disease to psychiatric conditions, and were compared with placebo or other treatments. Studies sponsored by industry reported greater benefits and fewer harmful side effects compared with studies that were not sponsored by industry. Papers describing industry-sponsored studies presented more favorable overall conclusions, and the results and conclusions sections in these papers were less likely to agree.

“Our results suggest that industry-sponsored drug and medical-device studies are more often favorable to the sponsor’s products than non–industry-sponsored studies,” said lead researcher Andreas Lundh. “These findings resonate with current calls for better access to information about how trials are carried out and raw data.”

The report says that the possible influence of study sponsorship is not always taken into account in medical guidelines and in assessments of the efficacy of drugs and medical devices. The researchers suggest that guidelines and reviews, including Cochrane systematic reviews, could improve transparency by disclosing sponsorship when results from industry-sponsored studies are reported and by regarding industry sponsorship as a factor that increases the risk of bias.

“Industry sponsorship should be reported in original published studies, but it must also be taken into account when results are reported on elsewhere,” said senior author Lisa Bero. “If we agree that industry sponsorship is an important source of bias, then we need to think about developing better methods for reporting, assessing, and handling industry bias in systematic reviews that evaluate the effects of drugs and devices.”

Sources: Wiley; December 11, 2012; and The Cochrane Library; December 12, 2012.

More Headlines

Atezolizumab in Combination with Chemotherapy is the Only First-line Cancer Immunotherapy for ES-SCLC
Pre-clinical Trials Showed Drug Inhibits Fibroblast Activity and Collagen Deposition
PARG Inhibitor Exploits Weakness, Kills Cells
Inexpensive, Wearable Therapy Increases Arm Mobility, Reduces Stiffness
California Woman Claimed Asbestos in Talc-Based Powder Caused Her Mesothelioma
Synergistic Effects Seen When Combined With Cisplatin in Mice
National Statistics Report Factors In Race, Ethnicity for the First Time
FDA Prioritizing Review of ARB Applications to Help Mitigate Drug Shortage
For Locally Advanced or Metastatic Triple-Negative Type Only